ArticleHypertension (Dallas, Tex. : 1979)2021
Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.
Abstract readComparative StudyMulticenter Study
In one paragraph
Article in Hypertension (Dallas, Tex. : 1979), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A meta-analysis investigating the efficacy and adverse events linked to sacubitril-valsartan in various heart failure subtypes.Clinical cardiology · 2024Pooled it
- Two-Drug Combinations Therapy of Different Doses of Valsartan Existing Diverse Significance for Hypertensive Patients.Reviews in cardiovascular medicine · 2023Pooled it
- Systematically exploring repurposing effects of antihypertensives.Pharmacoepidemiology and drug safety · 2022Pooled it
- Comparative efficacy and safety of fimasartan in patients with hypertension: A network meta-analysis of randomized controlled trials.Journal of clinical hypertension (Greenwich, Conn.) · 2022Pooled it
- Blood Pressure Variability and Outcomes Across Antihypertensive Regimens.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Intraoperative hypotension after remimazolam or propofol induction with sevoflurane maintenance in angiotensin II receptor blockers-treated patients: a randomized controlled trial.Scientific reports · 2025Trial
- Differential Sex-Specific Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blocker Therapy on Arterial Function in Hypertension: CALIBREX Trial.Hypertension (Dallas, Tex. : 1979) · 2022Trial
- Impact of Antihypertensive Drug Class on Outcomes in SPRINT.Hypertension (Dallas, Tex. : 1979) · 2022Trial
- From guidelines to practice: antihypertensive prescribing preferences in Türkiye-the APP-Türkiye study.Journal of human hypertension · 2026Article
- Cardiovascular Disease as a Risk Amplifier of COVID-19 Severity and a Potential Correlations to Long-Term Gastrointestinal Sequelae.Journal of racial and ethnic health disparities · 2026Article
- Comparative bleeding risk between angiotensin II receptor blockers with high versus low P-glycoprotein inhibitory activity in patients with atrial fibrillation receiving direct oral anticoagulants.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Subclinical Atherosclerosis, Hyperlipidemia and New-Onset Diabetes Should Not Be Ignored Despite Initial Angiographic Exclusion of Significant Atherosclerotic Occlusive Arterial Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular and non-cardiovascular outcomes in patients at high/very-high cardiovascular risk without heart failure: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trialsEuropean heart journal open · 2026Article
- Angiotensin-converting enzyme inhibitors show an edge over angiotensin II receptor blockers in cardiovascular outcomes.European heart journal open · 2026Article
- Pharmacovigilance and clinical insights into perindopril-induced thrombocytopenia: a case report of diagnostic challenges and therapeutic alternatives.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction.Addiction biology · 2026Review
- Current Management of Resistant Hypertension in Patients with Intracerebral Hemorrhage.International journal of molecular sciences · 2026Review
- Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- All in on ARBs: Is it time to fold the ACEIs?Canadian family physician Medecin de famille canadien · 2026Review
- Comparative Effectiveness of ACE Inhibitors and Angiotensin Receptor Blockers for Cardiovascular Disease Prevention in People Living with HIV and Hypertension.medRxiv : the preprint server for health sciences · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors.
RuiJun ChenDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York (R.C., P.B.R., G.H.).
Marc A SuchardDepartment of Biostatistics, Fielding School of Public Health, University of California, Los Angeles (M.A.S., M.J.S.).
Harlan M KrumholzSection of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT (H.M.K.).
Martijn J SchuemieDepartment of Biostatistics, Fielding School of Public Health, University of California, Los Angeles (M.A.S., M.J.S.).
Steven SheaDepartment of Medicine (S.S.), Columbia University, New York.
Jon DukeGeorgia Tech Research Institute, Georgia Tech College of Computing, Atlanta (J.D.).
Nicole PrattQuality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, Australia (N.P.).
Christian G ReichReal World Solutions, IQVIA, Cambridge, MA (C.G.R.).
David MadiganDepartment of Statistics (D.M.), Columbia University, New York.
Seng Chan YouDepartment of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea (S.C.Y.).
Patrick B RyanDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York (R.C., P.B.R., G.H.).
George HripcsakDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York (R.C., P.B.R., G.H.).
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MTechnology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2018 to 2026
$32.0MTraining in Biomedical Informatics at Columbia UniversityT15LM007079 · NLM · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI NOEMIE ELHADAD, GEORGE M HRIPCSAK · 1992 to 2026
$28.9MDISCOVERING AND APPLYING KNOWLEDGE IN CLINICAL DATABASESR01LM006910 · NLM · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HRIPCSAK, GEORGE M · 2000 to 2023
$10.6MNCATS NIH HHS UL1 TR001863NIAID NIH HHS U19 AI135995NLM NIH HHS R01 LM006910NLM NIH HHS T15 LM007079
Abstract
[Figure: see text].
Indexed as
AdolescentAdultAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsChildChild, PreschoolFemaleHumansHypertensionInfantMaleMiddle AgedRetrospective StudiesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive Agentsangiotensin receptorangiotensin receptor blockercardiovascular outcomeshypertensionsafety
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.